Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan versus loop diuretic for renal protection in CKD patients with moderate to severe edema
ChiCTR2200066643Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tolvaptan in chronic kidney disease (CKD) (3 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: estimated glomerular filtration rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
tolvaptan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2200066643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066643.